Summary
62 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 30 USD is left as net profit.
- It bought back its own shares for $8.36M in the last fiscal year, 3.7% of its market value.
What to watch
- Revenue fell by 9.7% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.2 USD for 1 USD of yearly profit. Over the last five years it was 19.4 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue fell by 1.8% a year over 5 years. Over the last 3 years it fell by 9.7% a year. Earnings per share fell by 8.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 44 USD
- Research and development 1.5 USD
- Sales and administration 25 USD
- Taxes and other -0.5 USD
- Net profit 30 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.2 USD
Out of every 100 USD of revenue, 30 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.75%
- Paid out of profit
- 37%
- Raised in a row
- 3 years
You receive $1.24 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.